Silicon Valley-based Medeloop, a platform designed to expedite clinical research using AI, has raised $15.5 million USD ($21 million CAD) in a Series A round. The funding was led by Canadian venture firm Inovia Capital, with contributions from Icon Ventures, General Catalyst, Maven Ventures, and others. This brings Medeloop’s total funding to $25.5 million USD ($35.8 million CAD).
Founded in 2021 by surgeon and entrepreneur Rene Caissie, Medeloop uses autonomous AI agents to streamline research tasks like data ingestion, analytics, grant writing, and manuscript production. Caissie’s personal journey to find a cure for his daughter’s Complex Regional Pain Syndrome inspired the venture.
“Our experience highlighted the inefficiencies in medical research and the critical need for innovative solutions,” said Caissie.
Medeloop’s partnerships include collaborations with McGill University, Fitbit, and Mila, a Montréal-based AI institute, enabling advanced data analysis and faster research outcomes.
Advertisement
From Medesync to Medeloop
Caissie, originally from New Brunswick, Canada, previously founded Medesync, an electronic medical records company sold to Telus. He also contributed to the development of Dorma Filtration’s N99 masks during the COVID-19 pandemic.
Scaling AI-Driven Innovation
The startup plans to use the funds to improve the speed and accuracy of its AI platform, addressing inefficiencies in clinical research. Inovia partner Magaly Charbonneau praised the leadership, stating, “Rene’s dual expertise as a surgeon and tech entrepreneur uniquely positions him to navigate this field.”
With a mission to transform medical research, the company is set to redefine how clinical trials are conducted, making healthcare innovation faster and more efficient.
